-
Uncategorized2 weeks agoDDW Highlights: 26 March 2026
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep...
-
Uncategorized2 weeks agoObesity could be treated without suppressing appetite
Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals. Researchers identified how brown fat cells, which are linked to weight loss, communicate...
-
Uncategorized2 weeks agoWhitepaper: Secure your place in the IND race
A new exclusive whitepaper is now available from Lonza entitled ‘Secure your place in the IND race with a rapid tox approach‘. Early tox material can...
-
Uncategorized2 weeks agoJust – Evotec Biologics enters $10m agreement with BARDA
Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to...
-
Uncategorized2 weeks ago
Beyond Buzzwords in Longevity Investing
In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers...
-
Uncategorized2 weeks ago
Leadership, Not Managers, More Likely To Drive Employees Away, BioSpace Finds
Among biopharma professionals surveyed by BioSpace, respect remains higher for managers than for CEOs, and unhappiness with company leadership had nearly 1 in 7 people looking...
-
Uncategorized2 weeks ago
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its mark. The president and CEO of...
-
Uncategorized2 weeks ago
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze...
-
Uncategorized2 weeks ago
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk...
-
Uncategorized2 weeks ago
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
